[General pharmacological studies of VP 16-213. Effect on the peripheral system].
The general pharmacological studies of VP 16-213, an antitumor agent, in the peripheral system were carried out by oral and i.v. administration with laboratory animals. VP 16-213 had no effect on the resting tone and spontaneous motility of all the isolated smooth muscle organs tested at concentrations of up to 10(-5) g/ml. VP 16-213 showed no significant influences on the neuromuscular transmission in the sciatic nerve-tibial muscle preparation of rabbits, on renal function in dogs and rats, on blood sugar level in rabbits, and on charcoal meal transport in mice. At a dose of 20 mg/kg, i.v., VP 16-213 reduced gastric secretion in rats. Antiinflammatory, local irritation and hemolytic effects were not observed after the administration of the drug. Single administration of VP 16-213 had orally no effect on the excretion of serum BSP in rats. However, successive administration of the drug (20 mg/kg/day) once daily for 10 days significantly depressed it. VP 16-213 decreased the number of hemolytic plaque forming cells in the spleens of immunized mice.
D000818:Animals; D000893:Anti-Inflammatory Agents; D001777:Blood Coagulation / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D003228:Conjunctiva / Q000187:drug effects; D004285:Dogs; D005047:Etoposide / Q000494:pharmacology*; D005260:Female; D006168:Guinea Pigs; D007166:Immunosuppressive Agents; D007413:Intestinal Mucosa / Q000187:drug effects; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects*; D010525:Peripheral Nerves / Q000187:drug effects*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains
D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D007166:Immunosuppressive Agents; D005047:Etoposide; D011034:Podophyllotoxin